# ![@CandelTx Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1080516344607584257.png) @CandelTx Candel Therapeutics

Candel Therapeutics posts on X about $cadl, ceo, data, in the the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1080516344607584257/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1080516344607584257/c:line/m:interactions.svg)

- [--] Week [-----] -67%
- [--] Month [-----] +282%
- [--] Months [------] +170%
- [--] Year [------] +89%

### Mentions: [--] [#](/creator/twitter::1080516344607584257/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1080516344607584257/c:line/m:posts_active.svg)

- [--] Month [--] -67%
- [--] Months [--] +85%
- [--] Year [--] +175%

### Followers: [---] [#](/creator/twitter::1080516344607584257/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1080516344607584257/c:line/m:followers.svg)

- [--] Week [---] +0.14%
- [--] Month [---] +1.90%
- [--] Months [---] +12%
- [--] Year [---] +35%

### CreatorRank: [---------] [#](/creator/twitter::1080516344607584257/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1080516344607584257/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  99.05% [finance](/list/finance)  7.62% [exchanges](/list/exchanges)  1.9% [travel destinations](/list/travel-destinations)  1.9% [financial services](/list/financial-services)  0.95%

**Social topic influence**
[$cadl](/topic/$cadl) #3, [ceo](/topic/ceo) 21.9%, [data](/topic/data) 20%, [in the](/topic/in-the) 11.43%, [we are](/topic/we-are) 6.67%, [business](/topic/business) 2.86%, [future](/topic/future) 2.86%, [advance](/topic/advance) 2.86%, [the first](/topic/the-first) 2.86%, [strong](/topic/strong) 2.86%

**Top accounts mentioned or mentioned by**
[@paulpetertak](/creator/undefined) [@nasdaq](/creator/undefined) [@pharmavoice](/creator/undefined) [@citeline](/creator/undefined) [@routeco145](/creator/undefined) [@nnchamber](/creator/undefined) [@neuroonc](/creator/undefined) [@sitcancers](/creator/undefined) [@jefferies](/creator/undefined) [@urologytimes](/creator/undefined) [@britsocimm](/creator/undefined) [@fiercebiotech](/creator/undefined) [@onclive](/creator/undefined) [@labiotecheu](/creator/undefined) [@baroneexpmed](/creator/undefined) [@bradloncar](/creator/undefined) [@biotechtv](/creator/undefined) [@medicinemakers](/creator/undefined) [@muralidharan125](/creator/undefined) [@checkorphan](/creator/undefined)

**Top assets mentioned**
[Candel Therapeutics, Inc. (CADL)](/topic/$cadl) [Trinity Capital Inc. (TRIN)](/topic/$trin)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Congratulations to our very own Dr. Estuardo Aguilar-Cordova for being picked by @nnchamber as one of the [--] Most Influential Business People of Color #Immunotherapy #oncology #GMCI https://www.nnchamber.com/bpoc-list/estuardo-aguilar-cor https://www.nnchamber.com/bpoc-list/estuardo-aguilar-cor"  
[X Link](https://x.com/CandelTx/status/1327752573584089088)  2020-11-14T23:17Z [---] followers, [--] engagements


"Pharma veteran and renowned immunologist @paulpetertak has joined Candel as our new CEO. Were also expanding our leadership team with new appointments including CFO CBO and CRO. Get the full details in our press release: https://www.businesswire.com/news/home/20201208005304/en/Candel-Therapeutics-Appoints-Pharma-Veteran-and-Immunologist-Paul-Peter-Tak-M.D.-Ph.D.-as-Chief-Executive-Officer-Expands-Leadership-Team-With-Chief-Financial-Officer-Chief-Business-Officer-and-Chief-Regulatory-Officer-Appointments"  
[X Link](https://x.com/CandelTx/status/1336297168974516225)  2020-12-08T13:10Z [---] followers, [--] engagements


"Were excited to join the @Nasdaq family Now #NasdaqListed and trading: $CADL. Learn more about our IPO here: https://bit.ly/3i5UcnL https://bit.ly/3i5UcnL"  
[X Link](https://x.com/CandelTx/status/1420448883268800514)  2021-07-28T18:19Z [---] followers, [--] engagements


"Today marks our one year anniversary on @Nasdaq We're extremely proud and grateful for our team members and supporters who helped us achieve this important milestone. Together we can work to create a better future for people diagnosed with cancer"  
[X Link](https://x.com/CandelTx/status/1552324115792404480)  2022-07-27T16:04Z [---] followers, [--] engagements


"We joined renowned #oncology experts for our R&D Day and provided an extensive update on our viral #immunotherapy pipeline including new #data from our #NSCLC and #HGG programs. Read highlights in the PR and view the event recording here: https://bit.ly/3UGwheG https://bit.ly/3UGwheG"  
[X Link](https://x.com/CandelTx/status/1600573279101931520)  2022-12-07T19:29Z [---] followers, [--] engagements


"Thank you to @PharmaVoice for including our CEO @paulpetertak among industry leaders sharing their outlook for pharma in [----]. Dr. Tak shares his perspective on why adaptability will define successful commercialization strategies moving forward. https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/ https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/"  
[X Link](https://x.com/CandelTx/status/2018338856848834986)  2026-02-02T15:00Z [---] followers, [----] engagements


"New in @NeuroOnc Our phase 1b trial of CAN-2409 + nivolumab in newly diagnosed high-grade glioma shows promising safety & survival data with immune activation supporting CAN-2409's pan-tumor potential. Read more: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-publication-phase-1b-clinical https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-publication-phase-1b-clinical"  
[X Link](https://x.com/CandelTx/status/1907180526986735677)  2025-04-01T21:17Z [---] followers, [----] engagements


"Watch our CEO @paulpetertak discuss the promising phase 2a results of CAN-2409 in pancreatic cancer showing median overall survival of [----] months vs [----] months in the control group with [--] patients still alive after extended follow-up. $CADL https://www.proactiveinvestors.com/companies/news/1067175/candel-therapeutics-ceo-discusses-promising-phase-2-pancreatic-cancer-trial-results-icymi-1067175.html https://www.proactiveinvestors.com/companies/news/1067175/candel-therapeutics-ceo-discusses-promising-phase-2-pancreatic-cancer-trial-results-icymi-1067175.html"  
[X Link](https://x.com/CandelTx/status/1914342038562107871)  2025-04-21T15:34Z [---] followers, [----] engagements


"We're pleased to announce Candel's participation in two investor conferences. We look forward to discussing our innovative viral immunotherapies & clinical progress with the investment community. See todays release for details: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences"  
[X Link](https://x.com/CandelTx/status/1919731666496438273)  2025-05-06T12:31Z [---] followers, [----] engagements


"For #MelanomaAwarenessMonth we're highlighting our promising CAN-3110 preclinical data in melanoma. CAN-3110 targets Nestin-positive cancer cells showing potential to expand beyond high-grade glioma into melanoma treatment and other indications. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting"  
[X Link](https://x.com/CandelTx/status/1920476950398685571)  2025-05-08T13:52Z [---] followers, [----] engagements


"Today we announced our Q1 [----] financial results and provided corporate updates on our development programs. Full details: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results"  
[X Link](https://x.com/CandelTx/status/1922263742219276436)  2025-05-13T12:12Z [---] followers, [----] engagements


"Candel will be participating in the Jefferies Healthcare Conference. We look forward to connecting with investors and sharing updates on our viral immunotherapy programs and recent data. $CADL #JefferiesHealthcare https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences"  
[X Link](https://x.com/CandelTx/status/1928085194998698436)  2025-05-29T13:45Z [---] followers, [---] engagements


"We're pleased to announce a $15M registered direct offering to advance pre-commercialization activities for CAN-2409 in prostate cancer. Supported by existing institutional investors and company leadership as we work to transform cancer treatment. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-15-million-registered-direct https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-15-million-registered-direct"  
[X Link](https://x.com/CandelTx/status/1937500356109565968)  2025-06-24T13:17Z [---] followers, [----] engagements


"Attending #ASTRO25 Dr. Gejerman will present our phase [--] prostate cancer study. The data represents potential progress for 65k men diagnosed annually with intermediate-to-high-risk localized prostate cancer who undergo radiotherapy with curative intent. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-phase-3-results-can-2409-localized https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-phase-3-results-can-2409-localized"  
[X Link](https://x.com/CandelTx/status/1968292751528620207)  2025-09-17T12:35Z [---] followers, [----] engagements


"October is National Healthy Lung Month. Our CAN-2409 NSCLC program shows promise: [----] months median survival vs 9.8-11.8 months with standard treatment in patients with progressive disease. Lung cancer claims 1.8M+ lives annually. Every breakthrough matters. #HealthyLungMonth"  
[X Link](https://x.com/CandelTx/status/1977736325169029404)  2025-10-13T14:00Z [---] followers, [---] engagements


"We are pleased to announce Dr. Bali Pulendran joins Candels Research Advisory Board. Dr. Pulendran is a leading systems immunology expert and Professor at Stanford. $CADL #Advisory https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-leading-systems-immunology-expert https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-leading-systems-immunology-expert"  
[X Link](https://x.com/CandelTx/status/1978795545788342591)  2025-10-16T12:09Z [---] followers, [----] engagements


"Tune in Our CEO @paulpetertak was invited to present at @sitcancers 40th Anniversary Annual Meeting next month in National Harbor MD. #SITC2025 #ProstateCancer https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting"  
[X Link](https://x.com/CandelTx/status/1980635421106184383)  2025-10-21T14:00Z [---] followers, [----] engagements


"Its Brain Tumor Awareness Week. Our CAN-3110 program targets recurrent high-grade glioma with oncolytic HSV approach. We are working hard to advance treatment options for challenging brain cancers. $CADL #BrainTumorAwareness"  
[X Link](https://x.com/CandelTx/status/1983202384202346585)  2025-10-28T16:01Z [---] followers, [----] engagements


"November is #LungCancerAwareness Month. Our CAN-2409 NSCLC program shows promise: [----] months median survival in ICI-refractory patients vs [--] months with standard of care chemotherapy. Lung cancer claims 1.8M+ lives annually. Every breakthrough matters. https://candeltx.com/patients/#step-25 https://candeltx.com/patients/#step-25"  
[X Link](https://x.com/CandelTx/status/1985371330590523429)  2025-11-03T15:39Z [---] followers, [----] engagements


"Our CEO @paulpetertak is delivering a keynote presentation at #PEGSEurope. He will discuss how Candels clinical-stage investigational immunotherapies cause in situ immunization against tumor antigens producing systemic & sustained anti-cancer effects. https://www.pegsummiteurope.com/next-generation-immunotherapies https://www.pegsummiteurope.com/next-generation-immunotherapies"  
[X Link](https://x.com/CandelTx/status/1988622983020027975)  2025-11-12T15:00Z [---] followers, [---] engagements


"We are seeing steady advancement across our pipeline and look forward to continued momentum as we head into [----]. Learn about the Q3 progress and anticipated plans for the rest of the year in the Q3 [----] financial press release: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2025-financial-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2025-financial-results"  
[X Link](https://x.com/CandelTx/status/1988963062204793284)  2025-11-13T13:32Z [---] followers, [----] engagements


"Our CEO @paulpetertak will share the latest corporate updates at the @Jefferies London Healthcare Conference this week. See the details here: $CADL #JefferiesHealthcare https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-jefferies-global-healthcare-0 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-jefferies-global-healthcare-0"  
[X Link](https://x.com/CandelTx/status/1990435010990555314)  2025-11-17T15:01Z [---] followers, [----] engagements


"We are thrilled to be a Scrip Awards finalist in TWO categories: - Best Oncology R&D Advance (CAN-2409 phase [--] in prostate cancer) - Biotech Company of the Year - Developmental Stage Thank you @Citeline for the recognition $CADL https://www.citeline.com/en/awards/scripawards https://www.citeline.com/en/awards/scripawards"  
[X Link](https://x.com/CandelTx/status/1993376503476707792)  2025-11-25T17:49Z [---] followers, [----] engagements


"Were hosting a Virtual R&D Day to discuss our cancer immunotherapy pipeline. The #event will feature insights from leading experts as we discuss the future of #cancer treatment. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025"  
[X Link](https://x.com/CandelTx/status/1995870827363910052)  2025-12-02T15:01Z [---] followers, [----] engagements


"Happening Today: Our Virtual R&D Day Weve gathered leading experts to explore Candels viral immunotherapy approach to cancer. The discussion will include insights into our CAN-2409 and CAN-3110 pipeline. Register now: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025"  
[X Link](https://x.com/CandelTx/status/1996928513765450005)  2025-12-05T13:03Z [---] followers, [---] engagements


"#ICYMI - Our Q3 financial results highlighted the significant progress across our cancer immunotherapy pipeline. From clinical advancements to strategic financing were positioning Candel for continued growth. Read more here: #CADL https://www.proactiveinvestors.com/companies/news/1082445/candel-therapeutics-highlights-3q-milestones-across-cancer-immunotherapy-pipeline-1082445.html https://www.proactiveinvestors.com/companies/news/1082445/candel-therapeutics-highlights-3q-milestones-across-cancer-immunotherapy-pipeline-1082445.html"  
[X Link](https://x.com/CandelTx/status/1998045139948687454)  2025-12-08T15:00Z [---] followers, [----] engagements


"Dr. Glen Gejerman spoke to @UrologyTimes about Candels phase [--] trial results for CAN-249 in localized intermediate- to high-risk prostate cancer presented at ASTRO [----]. Tune into this insightful video to hear more. https://www.urologytimes.com/view/glen-gejerman-md-highlights-phase-3-data-on-can-2409-in-localized-prostate-cancer https://www.urologytimes.com/view/glen-gejerman-md-highlights-phase-3-data-on-can-2409-in-localized-prostate-cancer"  
[X Link](https://x.com/CandelTx/status/1998769889046061088)  2025-12-10T15:00Z [---] followers, [----] engagements


"As [----] draws to a close we reflect on what an incredible year it has been. Were grateful for our dedicated team supportive partners and the patients who inspire our mission every day. Wishing everyone peace joy and continued optimism in the fight against cancer"  
[X Link](https://x.com/CandelTx/status/2003495594145296737)  2025-12-23T15:59Z [---] followers, [---] engagements


"Next week our executive team will be in San Francisco for the J.P. Morgan Healthcare Conference. We look forward to connecting with industry leaders and the investor community. Hope to see you there #JPM2026 #Healthcare #Biotech $CADL"  
[X Link](https://x.com/CandelTx/status/2008554314508247390)  2026-01-06T15:00Z [---] followers, [----] engagements


"#ICYMI - Our Virtual R&D Day brought together immunotherapy legends alongside leading oncologists to discuss our viral immunotherapy platform CAN-2409s path to BLA submission and updates across our clinical pipeline. Watch the full webcast $CADL https://ir.candeltx.com/events/event-details/candel-therapeutics-host-virtual-rd-event https://ir.candeltx.com/events/event-details/candel-therapeutics-host-virtual-rd-event"  
[X Link](https://x.com/CandelTx/status/2013990172803604612)  2026-01-21T15:00Z [---] followers, [----] engagements


"NSCLC remains challenging to treat. Our viral immunotherapy CAN-2409 showed encouraging results in phase [--] achieving [--] months median overall survival vs. [--] months reported in the literature for second-line chemotherapy. Next is phase [--] trial initiation in Q2 [----]. $CADL"  
[X Link](https://x.com/CandelTx/status/2016164442287816876)  2026-01-27T15:00Z [---] followers, [----] engagements


"Our phase [--] trial of CAN-2409 in intermediate-to-high-risk localized prostate cancer showed a 30% improvement in disease-free survival and 80% complete pathological response vs. 64% in controls. BLA submission planned for Q4 [----]. $CADL https://candeltx.com/ https://candeltx.com/"  
[X Link](https://x.com/CandelTx/status/2016889173903392822)  2026-01-29T15:00Z [---] followers, [----] engagements


"Were participating in the H.C. Wainwright Annual Global Investment Conference. With $100.7 million in cash as of June [--] [----] were well-positioned to fund operations into Q1 [----] and execute on key value-creating milestones. $CADL #HCWainwright https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences"  
[X Link](https://x.com/CandelTx/status/1965038829972099182)  2025-09-08T13:05Z [---] followers, [----] engagements


"Well be at #SITC2025 Presenting posters on our enLIGHTEN platform and CAN-2409 in NSCLC plus our CEO @paulpetertak will speak on our phase [--] prostate cancer data. See the curtain raiser: #Immunotherapy #ProstateCancer #NSCLC https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting"  
[X Link](https://x.com/CandelTx/status/1974099642666176674)  2025-10-03T13:10Z [---] followers, [---] engagements


"Well be sharing data from our CAN-2409 program in NSCLC & and our enLIGHTEN Discovery Platform. Our CEO @paulpetertak will give a presentation on the phase [--] clinical trial of CAN-2409 in prostate cancer. More details: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025"  
[X Link](https://x.com/CandelTx/status/1985712732239237616)  2025-11-04T14:16Z [---] followers, [----] engagements


"#ICYMI - We secured a $130M term loan facility with Trinity Capital strengthening our runway through key milestones: - BLA submission Q4 [----] - Commercial launch prep - NSCLC pivotal studies Q2 [----] $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-enters-130-million-term-loan-facility https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-enters-130-million-term-loan-facility"  
[X Link](https://x.com/CandelTx/status/1988260669574042068)  2025-11-11T15:00Z [---] followers, [----] engagements


"#TBT to last month when Candel was honored with the [----] Scrip Award for Best Oncology R&D Advance This recognition celebrates our successful phase [--] study of CAN-2409 in localized prostate cancer. Thank you to @Citeline for this honor. $CADL https://citeline.com/en/awards/scripawards https://citeline.com/en/awards/scripawards"  
[X Link](https://x.com/CandelTx/status/2009641526230405170)  2026-01-09T15:00Z [---] followers, [----] engagements


"Read this article highlighting our viral immunotherapy approach and promising clinical results across multiple solid tumors. It covers our positive phase [--] data in prostate cancer and our plans to file a BLA for CAN-2409 in late [----]. $CADL https://www.nature.com/articles/d43747-025-00101-6 https://www.nature.com/articles/d43747-025-00101-6"  
[X Link](https://x.com/CandelTx/status/2010728619291677089)  2026-01-12T15:00Z [---] followers, [----] engagements


"This #WorldCancerDay our commitment remains clear: developing innovative immunotherapies that harness each patients own immune system to fight cancer. Were advancing two clinical-stage immunotherapy platforms targeting some of cancers toughest challenges"  
[X Link](https://x.com/CandelTx/status/2019063569749324112)  2026-02-04T15:00Z [---] followers, [---] engagements


"Were excited to share that our Chief Scientific Officer Francesca Barone will be presenting at the 7th Glioblastoma Drug Development Summit next week in Boston. #Glioblastoma #CancerResearch https://glioblastoma-drugdevelopment.com/speaker/francesca-barone/ https://glioblastoma-drugdevelopment.com/speaker/francesca-barone/"  
[X Link](https://x.com/CandelTx/status/2021237912449200209)  2026-02-10T15:00Z [---] followers, [---] engagements


"President and CEO @paulpetertak MD PhD FMedSci is delivering a keynote at the @britsocimm Immune Therapies Summit next week in Cambridge Join us to explore breakthrough approaches in immune therapeutics. #ImmuneTherapies24 #Immunology $CADL https://web-eur.cvent.com/event/ffa03d05-261d-41c7-9633-186758c1883b/summarytm=_B4a8-iJwdB-eiyRO4nk6r-wP4If9zTYweHKsyXJqSY https://web-eur.cvent.com/event/ffa03d05-261d-41c7-9633-186758c1883b/summarytm=_B4a8-iJwdB-eiyRO4nk6r-wP4If9zTYweHKsyXJqSY"  
[X Link](https://x.com/anyuser/status/1859228052506468440)  2024-11-20T13:31Z [---] followers, [----] engagements


"This #WorldPancreaticCancerDay were highlighting our ph [--] clinical trial of CAN-2409 + standard care (SoC) in pancreatic cancer. Patients achieved estimated [----] months median survival in the CAN-2409 + SoC group vs [----] months in the SoC control group. https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"  
[X Link](https://x.com/CandelTx/status/1859611454409740525)  2024-11-21T14:54Z [---] followers, [---] engagements


"Did you know CAN-2409 our investigational viral immunotherapy is designed to trigger the bodys anti-tumor immune response when combined with valacyclovir. Prostate data readouts expected later this year. Learn how CAN-2409 works: $CADL https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"  
[X Link](https://x.com/CandelTx/status/1861070990530302439)  2024-11-25T15:34Z [---] followers, [----] engagements


"Our CEO @paulpetertak MD PhD FMedSci sat down with Proactive Investors. He discussed our upcoming prostate cancer trial readouts for CAN-2409 and highlighted promising developments with CAN-3110 in #glioblastoma and #melanoma. $CADL https://www.youtube.com/watchv=alJlb7qTx3M https://www.youtube.com/watchv=alJlb7qTx3M"  
[X Link](https://x.com/CandelTx/status/1861424797135061480)  2024-11-26T15:00Z [---] followers, [----] engagements


"Could CAN-2409 change how we treat localized #ProstateCancer Our P3 trial evaluates CAN-2409 an investigational immunotherapy for patients with intermediate-high risk prostate cancer. Our goal is disease-free survival. Learn more: $CADL https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"  
[X Link](https://x.com/CandelTx/status/1861787210577530963)  2024-11-27T15:00Z [---] followers, [----] engagements


"Candel is proud to participate in #Movember supporting vital awareness for men's health initiatives. This cause resonates deeply with our mission as we advance our clinical trials in prostate cancer treatment. #MensHealth #ProstateCancer $CADL https://us.movember.com/ https://us.movember.com/"  
[X Link](https://x.com/CandelTx/status/1862512042118164551)  2024-11-29T15:00Z [---] followers, [----] engagements


"Our comprehensive clinical development program for CAN-2409 in localized #ProstateCancer includes: - Phase 2b in low-to-intermediate: [---] patients enrolled - Phase [--] in intermediate-high risk: [---] patients enrolled $CADL https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"  
[X Link](https://x.com/CandelTx/status/1864332392132997423)  2024-12-04T15:34Z [---] followers, [----] engagements


"We're pleased to share recent coverage highlighting our phase 2b and phase [--] prostate cancer clinical trials and anticipated data readouts. These trials represent key milestones as we advance novel treatments for cancer patients. $CADL https://www.proactiveinvestors.com/companies/news/1061802/candel-therapeutics-is-pushing-for-a-paradigm-shift-in-cancer-treatment-1061802.html https://www.proactiveinvestors.com/companies/news/1061802/candel-therapeutics-is-pushing-for-a-paradigm-shift-in-cancer-treatment-1061802.html"  
[X Link](https://x.com/CandelTx/status/1865063768943697935)  2024-12-06T16:00Z [---] followers, [----] engagements


"A new article by our CEO @paulpetertak MD PhD FMedSci explores transforming clinical trials for prostate cancer through patient-focused endpoints and innovative trial design. Read more: #ProstateCancer $CADL https://www.clinicalleader.com/doc/what-s-needed-to-transform-clinical-trials-in-early-stage-prostate-cancer-0001 https://www.clinicalleader.com/doc/what-s-needed-to-transform-clinical-trials-in-early-stage-prostate-cancer-0001"  
[X Link](https://x.com/CandelTx/status/1866525424185970712)  2024-12-10T16:48Z [---] followers, [----] engagements


"Our CMO Garrett Nichols M.D. M.S. discusses our phase [--] trial of CAN-2409 - potentially the first new treatment for localized prostate cancer in decades. Watch: #ProstateCancer $CADL https://www.youtube.com/watchv=iv3HFVKsunM https://www.youtube.com/watchv=iv3HFVKsunM"  
[X Link](https://x.com/CandelTx/status/1866589225962938834)  2024-12-10T21:02Z [---] followers, [----] engagements


"Were proud to announce topline data from our pivotal P3 trial investigating CAN-2409 in intermediate-high risk localized prostate cancer a key milestone in our mission to develop innovative treatment options for cancer patients. See the results: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint"  
[X Link](https://x.com/anyuser/status/1866872225866961012)  2024-12-11T15:46Z [---] followers, [----] engagements


"As [----] draws to a close we're grateful for our team partners & the patients who inspire us. Wishing everyone a peaceful holiday season & continued hope in advancing cancer treatment. #BiotechCommunity #Innovation $CADL"  
[X Link](https://x.com/CandelTx/status/1871209330797580305)  2024-12-23T15:00Z [---] followers, [----] engagements


"2024 brought positive topline data readouts for our phase [--] prostate cancer clinical trial and encouraging results across our pipeline. As we welcome [----] we're energized by our progress in advancing novel cancer treatments. Here's to continuing our mission in the new year"  
[X Link](https://x.com/CandelTx/status/1874833112946888975)  2025-01-02T15:00Z [---] followers, [----] engagements


"#ICYMI Our phase [--] trial of CAN-2409 met its primary endpoint in localized #ProstateCancer cancer showing significant improvement in disease-free survival. This could be the first major advancement for this indication in decades. @FierceBiotech: $CADL https://www.fiercebiotech.com/biotech/candel-burns-bright-phase-3-prostate-cancer-win-sends-stock-200 https://www.fiercebiotech.com/biotech/candel-burns-bright-phase-3-prostate-cancer-win-sends-stock-200"  
[X Link](https://x.com/anyuser/status/1876684399812423922)  2025-01-07T17:36Z [---] followers, [----] engagements


"Entering [----] with strong momentum Successes in [----] include positive P3 data for CAN-2409 in prostate cancer & encouraging survival data in pancreatic cancer & NSCLC. We remain focused on advancing viral immunotherapies to help patients fight cancer. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-provides-corporate-update-and-highlights https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-provides-corporate-update-and-highlights"  
[X Link](https://x.com/CandelTx/status/1878790549181718697)  2025-01-13T13:05Z [---] followers, [----] engagements


"Our enLIGHTEN Discovery Platform represents a revolutionary step forward in viral immunotherapy development. This systematic data-driven platform combines advanced analytics with human biology to create precisely engineered HSV-based gene constructs. https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"  
[X Link](https://x.com/CandelTx/status/1879910263840702814)  2025-01-16T15:15Z [---] followers, [----] engagements


"ICYMI: In [----] we successfully completed our public offering raising $92M to advance our cancer treatment pipeline including BLA preparation for CAN-2409 in prostate cancer. Thank you for supporting our mission #BiotechNews $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-closing-public-offering-and-full https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-closing-public-offering-and-full"  
[X Link](https://x.com/anyuser/status/1882445457500090753)  2025-01-23T15:09Z [---] followers, [---] engagements


"Our successful phase [--] results for CAN-2409 in prostate cancer validate our viral immunotherapy approach and position us to transform treatment options for patients. Read more in @PharmaVoice: #BiotechNews $CADL https://www.pharmavoice.com/news/candel-therapeutics-viral-immunotherapy-prostate-cancer-layoffs/736855/ https://www.pharmavoice.com/news/candel-therapeutics-viral-immunotherapy-prostate-cancer-layoffs/736855/"  
[X Link](https://x.com/CandelTx/status/1883905563945271655)  2025-01-27T15:51Z [---] followers, [----] engagements


"Last month we announced exciting results from our phase [--] CAN-2409 trial in prostate cancer showing significant improvements in disease-free survival and pathological complete response rates. Read in @onclive: #ProstateCancer #ClinicalTrials $CADL https://www.onclive.com/view/can-2409-improves-dfs-in-intermediate-high-risk-localized-prostate-cancer https://www.onclive.com/view/can-2409-improves-dfs-in-intermediate-high-risk-localized-prostate-cancer"  
[X Link](https://x.com/CandelTx/status/1884630609164714138)  2025-01-29T15:52Z [---] followers, [---] engagements


"ICYMI: We're starting [----] with strong momentum & clear direction. Our lead candidate CAN-2409 shows promising phase [--] results in prostate cancer. We're advancing toward BLA submission with clear momentum and $103M to fund operations into Q1 [----]. $CADL https://www.proactiveinvestors.com/companies/news/1064164/candel-therapeutics-advancing-lead-candidate-targeting-prostate-cancer-towards-fda-submission-1064164.html https://www.proactiveinvestors.com/companies/news/1064164/candel-therapeutics-advancing-lead-candidate-targeting-prostate-cancer-towards-fda-submission-1064164.html"  
[X Link](https://x.com/CandelTx/status/1886835927915339852)  2025-02-04T17:55Z [---] followers, [----] engagements


"We're approaching an important milestone in our pancreatic cancer program. Updated overall survival data from our phase 2a clinical trial of CAN-2409 is expected this quarter. Stay tuned for updates on this program $CADL"  
[X Link](https://x.com/CandelTx/status/1890408221031969180)  2025-02-14T14:30Z [---] followers, [----] engagements


"This #CancerPreventionMonth we recognize the importance of research education and community support in the fight against cancer. As we develop new therapeutic options we stand with patients healthcare providers and researchers united to transform cancer care"  
[X Link](https://x.com/CandelTx/status/1892582516986417513)  2025-02-20T14:30Z [---] followers, [----] engagements


"Today we have announced positive final survival data from our phase [--] clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Data showed median overall survival of [----] months with CAN-2409 vs. [----] months in control group. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-final-survival-data https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-final-survival-data"  
[X Link](https://x.com/CandelTx/status/1894420337770528948)  2025-02-25T16:12Z [---] followers, [----] engagements


"Investigational medicine CAN-3110 is breaking new ground in treating high-grade glioma. Engineered to target cancer cells while protecting healthy brain tissue with promising clinical activity in a phase 1b clinical trial. $CADL https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"  
[X Link](https://x.com/CandelTx/status/1894774807536812409)  2025-02-26T15:41Z [---] followers, [----] engagements


"Honored to be recognized by @Labiotech_eu for including Candel among [--] cancer vaccine biotechs to watch. Our CAN-2409 showed compelling results in prostate & pancreatic cancer & our continued work with CAN-3110 in high-grade glioma. $CADL https://www.labiotech.eu/best-biotech/cancer-vaccine-companies/ https://www.labiotech.eu/best-biotech/cancer-vaccine-companies/"  
[X Link](https://x.com/CandelTx/status/1907461792843890930)  2025-04-02T15:55Z [---] followers, [----] engagements


"The FDA has granted RMAT designation to CAN-2409 for localized prostate cancer in patients with intermediate-to-high-risk disease expediting development & review. This supports our path toward BLA submission anticipated for end of [----]. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced"  
[X Link](https://x.com/CandelTx/status/1927701118148026832)  2025-05-28T12:18Z [---] followers, [----] engagements


"Join our investor conference call on Tuesday June [--] at 1:00 PM ET following our #ASCO25 presentation. Our management team & leading prostate cancer specialists will discuss our phase [--] CAN-2409 results. Find more details here: $CADL #ProstateCancer https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-investor-conference-call-featuring https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-investor-conference-call-featuring"  
[X Link](https://x.com/CandelTx/status/1928496734902071713)  2025-05-30T17:00Z [---] followers, [---] engagements


"Last week we announced the appointment of Maha Radhakrishnan M.D. to our Board of Directors Maha brings 20+ years of biotech leadership experience in product development & commercialization. #Leadership #CancerTherapeutics $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-maha-radhakrishnan-md-its-board https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-maha-radhakrishnan-md-its-board"  
[X Link](https://x.com/CandelTx/status/1932815265596580121)  2025-06-11T15:00Z [---] followers, [---] engagements


"We're pleased to announce Charles Schoch as our new CFO His understanding of our business will be instrumental as we advance our clinical pipeline prepare for BLA submission for CAN-2409 in localized prostate cancer and execute on corporate goals. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-charles-schoch-chief-financial https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-charles-schoch-chief-financial"  
[X Link](https://x.com/CandelTx/status/1937120839431860634)  2025-06-23T12:09Z [---] followers, [----] engagements


"Exciting milestone The EMA granted Orphan Drug Designation for CAN-2409 in pancreatic cancer. This adds to our FDA Orphan Drug & Fast Track Designations reinforcing the unmet need in this disease. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-ema-orphan-designation-can-2409 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-ema-orphan-designation-can-2409"  
[X Link](https://x.com/CandelTx/status/1948416121440219315)  2025-07-24T16:12Z [---] followers, [----] engagements


"Excited to announce Carl H. June MD CAR-T cell immunotherapy pioneer has joined Candels Research Advisory Board Dr. Junes expertise in immunotherapy for cancer will be invaluable as we advance our viral immunotherapy programs. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-renowned-immunotherapy-pioneer-carl https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-renowned-immunotherapy-pioneer-carl"  
[X Link](https://x.com/CandelTx/status/1962854404295409733)  2025-09-02T12:25Z [---] followers, [---] engagements


"Were attending Citis [----] BioPharma Back to School Conference in Boston. Our CEO @PaulPeterTak will present our corporate strategy across multiple solid tumor indications. $CADL #CitiBioPharma #ProstateCancer https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences"  
[X Link](https://x.com/CandelTx/status/1963211340098552246)  2025-09-03T12:03Z [---] followers, [---] engagements


"Exciting milestone ahead with CAN-2409 targeting a late [----] U.S. filing after phase [--] prostate cancer success. With strong cash position through early [----] our viral immunotherapy continues showing promise across multiple cancer types. $CADL https://www.proactiveinvestors.com/companies/news/1076801/candel-therapeutics-secures-rmat-for-prostate-cancer-icymi-1076801.html https://www.proactiveinvestors.com/companies/news/1076801/candel-therapeutics-secures-rmat-for-prostate-cancer-icymi-1076801.html"  
[X Link](https://x.com/CandelTx/status/1970488533207962066)  2025-09-23T14:00Z [---] followers, [----] engagements


"Were presenting our phase [--] CAN-2409 localized prostate cancer trial at #ASTRO2025 with a subanalysis focused on type of radiation therapy used in the trial. #ProstateCancer #ClinicalData #RadiationOncology https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-phase-3-clinical-trial-can-2409 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-phase-3-clinical-trial-can-2409"  
[X Link](https://x.com/CandelTx/status/1972634605254520935)  2025-09-29T12:08Z [---] followers, [----] engagements


"Dr. John E. Sylvester from Atlantic Urology Clinics. presented CAN-2409 phase [--] data in an oral presentation at Future Directions in Urology Symposium. Thank you to the urology community for the engaging discussions and valuable feedback. $CADL #UrologyCongress"  
[X Link](https://x.com/CandelTx/status/1975190279113019776)  2025-10-06T13:23Z [---] followers, [---] engagements


"Congratulations to Candels Chief Regulatory Officer Susan Stewart on receiving the regulatory profession's highest honor - the RAPS Founders Award $CADL #RAPSAwards #RegulatoryAffairs https://www.raps.org/news-and-articles/news-articles/2025/7/raps-honors-9-regulatory-professionals-and-one-org https://www.raps.org/news-and-articles/news-articles/2025/7/raps-honors-9-regulatory-professionals-and-one-org"  
[X Link](https://x.com/CandelTx/status/1975961964636418367)  2025-10-08T16:30Z [---] followers, [----] engagements


"Candel's CSO @baroneExpMed will be attending the BofA Securities Merrill Lynch Global Healthcare Conference. We are looking forward to sharing our scientific progress and clinical developments. $CADL #BofAGlobalHC https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences"  
[X Link](https://x.com/CandelTx/status/1922653261892313309)  2025-05-14T14:00Z [---] followers, [---] engagements


"Dr. DeWeese Professor Dean of the Medical Faculty & CEO of Johns Hopkins will present our phase [--] CAN-2409 prostate cancer trial results at #ASCO2025. This therapy could change the standard of care for localized prostate cancer. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-positive-phase-3-can-2409-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-positive-phase-3-can-2409-results"  
[X Link](https://x.com/CandelTx/status/1925661344491003954)  2025-05-22T21:13Z [---] followers, [----] engagements


"Pharma Features spoke to our CTDO Dr. Tyagarajan She discusses how her cross-platform expertise supports the advancement of Candel's leading adenoviral platform HSV platform and enLIGHTEN Discovery Platform. Read here: https://pharmafeatures.com/enhancing-analytical-method-development-supporting-cohesive-cmc-integration-across-drug-lifecycle-management-with-seshu-tyagarajan-candel-therapeutics/ https://pharmafeatures.com/enhancing-analytical-method-development-supporting-cohesive-cmc-integration-across-drug-lifecycle-management-with-seshu-tyagarajan-candel-therapeutics/"  
[X Link](https://x.com/CandelTx/status/1936076779082404094)  2025-06-20T15:00Z [---] followers, [---] engagements


"We're pleased to be added to multiple Russell Value indexes in [----] reconstitution including Russell [----] Value Small Cap Value [----] Value Microcap Value & 3000E Value indexes. We also maintained our membership in the Russell [----] Index. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-expands-russell-index-presence-addition https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-expands-russell-index-presence-addition"  
[X Link](https://x.com/CandelTx/status/1942969526032695640)  2025-07-09T15:30Z [---] followers, [----] engagements


"Our CEO @paulpetertak will present at the 44th Annual Canaccord Genuity Growth Conference. Be sure to connect with us if you're attending the conference. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-canaccord-genuity-45th-annual-growth https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-canaccord-genuity-45th-annual-growth"  
[X Link](https://x.com/CandelTx/status/1954913298480058488)  2025-08-11T14:30Z [---] followers, [----] engagements


"Today we announced our financial results and provided corporate updates on our development programs. Progress on our BLA preparations for CAN-2409 in prostate cancer and updates on our financial position as we execute on key value-creating milestones. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-second-quarter-2025-financial https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-second-quarter-2025-financial"  
[X Link](https://x.com/CandelTx/status/1956003469279592540)  2025-08-14T14:42Z [---] followers, [---] engagements


"Today we announced presentations at [--] upcoming investor conferences in September Join us in Boston & NYC as we discuss our viral immunotherapy pipeline including CAN-2409s phase [--] success in prostate cancer. Details: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences"  
[X Link](https://x.com/CandelTx/status/1961051853166162190)  2025-08-28T13:02Z [---] followers, [----] engagements


"We are presenting at Cantor Global Healthcare Conference in NYC. Our CEO @PaulPeterTak will discuss CAN-2409s 30% improvement in disease-free survival for localized prostate cancer and our clinical pipeline. $CADL #CantorHealthcare #CancerResearch https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences"  
[X Link](https://x.com/CandelTx/status/1963553903665967328)  2025-09-04T10:45Z [---] followers, [----] engagements


"November is Movember a global movement raising awareness for mens health. Our CAN-2409 program for localized prostate cancer is advancing toward a Biologics License Application submission to the FDA in Q4 [----] following positive phase [--] results. https://candeltx.com/patients/#step-22 https://candeltx.com/patients/#step-22"  
[X Link](https://x.com/CandelTx/status/1987898249416442165)  2025-11-10T15:00Z [---] followers, [---] engagements


"Our preclinical data on CAN-3110's potential in #melanoma demonstrates tumor-specific activity & tumor regression in models with Ras-Raf pathway alterations supporting CAN-3110's use beyond its current development in rHGG. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-fourth-quarter-and-full-year-2024 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-fourth-quarter-and-full-year-2024"  
[X Link](https://x.com/CandelTx/status/1910346715258847538)  2025-04-10T14:58Z [---] followers, [---] engagements


"Our positive phase [--] results in localized prostate cancer will be featured at #ASCO2025 Dr. Theodore DeWeese Dean of the Medical Faculty & CEO of Johns Hopkins Medicine will present data showing reduced cancer recurrence risk after CAN-2409. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-oral-presentation-positive-phase-3 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-oral-presentation-positive-phase-3"  
[X Link](https://x.com/CandelTx/status/1915136627501904205)  2025-04-23T20:12Z [---] followers, [----] engagements


"#ICYMI: We published phase 1b clinical trial data in Neuro-Oncology that shows CAN-2409 plus nivolumab with standard of care demonstrated promising safety and potential survival benefit in newly diagnosed high-grade glioma patients. Read more: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-publication-phase-1b-clinical https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-publication-phase-1b-clinical"  
[X Link](https://x.com/CandelTx/status/1918354538668437800)  2025-05-02T17:18Z [---] followers, [---] engagements


"Our phase [--] trial data for CAN-2409 in prostate cancer will be presented at #ASCO2025 by Dr. DeWeese Dean of Medical Faculty & CEO at Johns Hopkins. The findings represent the first potential new treatment for localized prostate cancer in over [--] years. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-positive-phase-3-can-2409-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-positive-phase-3-can-2409-results"  
[X Link](https://x.com/CandelTx/status/1929530984585683248)  2025-06-02T13:30Z [---] followers, [----] engagements


"#ICYMI @BradLoncar at @BiotechTV and our CEO @paulpetertak discussed CAN-2409's phase [--] prostate cancer data and our strategy across multiple solid tumors at #ASCO25 Watch: https://www.biotechtv.com/post/candel-therapeutics-asco-2025 https://www.biotechtv.com/post/candel-therapeutics-asco-2025"  
[X Link](https://x.com/CandelTx/status/1947680535385362614)  2025-07-22T15:30Z [---] followers, [---] engagements


"We released updated phase 1b survival data for CAN-3110 in recurrent high-grade glioma. Science Translational Medicine published results from an analysis of serial tumor biopsies from [--] patients treated with CAN-3110 in Cohort C of the ongoing trial. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-interim-data-after https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-interim-data-after"  
[X Link](https://x.com/CandelTx/status/1978073912832328025)  2025-10-14T12:22Z [---] followers, [----] engagements


"Our enLIGHTEN platform uses #AI to design cancer immunotherapies. At #SITC2025 were presenting data in models of breast cancer showing this therapy achieved: - 60% tumor suppression - 2.7x increase in CD8+ T cells - Synergistic immune activation https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025"  
[X Link](https://x.com/CandelTx/status/1986795976237977886)  2025-11-07T14:00Z [---] followers, [---] engagements


"President & CEO @paulpetertak MD PhD FMedSci will serve as a keynote speaker and discuss Candels strategic approach developing viral immunotherapies to treat cancer at the Targeting share mechanisms in immune-mediated inflammatory diseases Grantees symposium this week"  
[X Link](https://x.com/CandelTx/status/1679537095566581780)  2023-07-13T17:03Z [---] followers, [---] engagements


"Candel is pleased to announce the U.S. FDA granted Fast Track Designation for its lead investigational medicine CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with borderline resectable PDAC to improve overall survival. Read more: https://bit.ly/4akp3q3 https://bit.ly/4akp3q3"  
[X Link](https://x.com/CandelTx/status/1734560883970384088)  2023-12-12T13:08Z [---] followers, [---] engagements


"President and CEO @paulpetertak MD PhD FMedSci will discuss the potential of $CADL's investigational medicine CAN-3110 as a well-tolerated and active cancer treatment at the Oncolytic Virotherapy Summit on December 13th at 4:15 pm ET. Learn more: https://bit.ly/3GoMwIW https://bit.ly/3GoMwIW"  
[X Link](https://x.com/CandelTx/status/1734936216368472402)  2023-12-13T14:00Z [---] followers, [---] engagements


"We're excited about the transformative potential of our promising and diversified immunotherapy pipeline. [----] will be a year of great progress with an anticipated six data readouts across our three innovative platforms. Learn more here: https://bit.ly/3UsTKUb https://bit.ly/3UsTKUb"  
[X Link](https://x.com/CandelTx/status/1754491943395185128)  2024-02-05T13:07Z [---] followers, [---] engagements


"We are pleased to share positive updated survival data from the P2 trial of CAN-2409 in non-metastatic pancreatic cancer. Data reveal notable improvements in median overall survival & safety supporting multiple injections of CAN-2409 were well tolerated. https://bit.ly/3xhLgWu https://bit.ly/3xhLgWu"  
[X Link](https://x.com/CandelTx/status/1775857432419582349)  2024-04-04T12:06Z [---] followers, [----] engagements


"Congrats to $CADL President and CEO @paulpetertak MD PhD FMedSci for making the @medicine_makers Power list for the 2nd year in a row Each year [--] individuals are recognized for driving innovation & inspiration in biopharma. Learn more here: https://themedicinemaker.com/awards/power-list/2024 https://themedicinemaker.com/awards/power-list/2024"  
[X Link](https://x.com/CandelTx/status/1779857210136215745)  2024-04-15T13:00Z [---] followers, [---] engagements


"In honor of National #VolunteerMonth Candel is celebrating the power of giving back. Whether it's lending a hand at a soup kitchen mentoring youth or cleaning up parks every act makes a difference. Let's inspire kindness & compassion together #NationalVolunteerMonth"  
[X Link](https://x.com/CandelTx/status/1783843472883220595)  2024-04-26T13:00Z [---] followers, [---] engagements


"$CADL Interim CFO Charles Schoch and VP of Investor Relations and Business Development Ted Jenkins will participate in the 44th Annual Canaccord Genuity Growth Conference taking place in Boston MA Aug 13-14th. Be sure to connect if youre attending the conference"  
[X Link](https://x.com/CandelTx/status/1821531814189822354)  2024-08-08T13:00Z [---] followers, [---] engagements


"On #WorldCancerResearchDay we honor the relentless pursuit of innovation in the fight against cancer. We're developing 2nd generation viral immunotherapies to empower the immune system to combat cancer. Join us as we push the boundaries of science and bring new hope. #WCRD2024"  
[X Link](https://x.com/CandelTx/status/1838564046284435831)  2024-09-24T13:00Z [---] followers, [---] engagements


"President and CEO @paulpetertak MD PhD FMedSci will join a panel with Sushil Patel CEO of Replimune at the ROTH Healthcare Opportunities Conference. The panel will cover product differentiation data across indications development steps & manufacturing capabilities"  
[X Link](https://x.com/anyuser/status/1843293993460719883)  2024-10-07T14:15Z [---] followers, [---] engagements


"Only 15-40% of advanced #NSCLC patients respond to standard ICIs. This #HealthyLungMonth we're highlighting the need for new treatments. Candel is testing CAN-2409 a viral immunotherapy showing promise in progressive disease despite ICI treatment. https://www.candeltx.com/patients/#step-25 https://www.candeltx.com/patients/#step-25"  
[X Link](https://x.com/CandelTx/status/1844392453496869230)  2024-10-10T15:00Z [---] followers, [---] engagements


"For men with localized #ProstateCancer treatment decisions are complex. While active surveillance prevents over-treatment in low-risk cases many see progression over time. We're exploring new approaches to bridge this gap through our phase 2b trial. https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"  
[X Link](https://x.com/CandelTx/status/1859975278899925078)  2024-11-22T15:00Z [---] followers, [---] engagements


"Fireside chat: Our CEO @paulpetertak discusses CAN-2409's positive phase [--] results in prostate cancer and Candel's full oncology pipeline with HCW Research Analyst Vernon Bernardino. View here: #CancerResearch #BioTech $CADL https://ir.candeltx.com/events/event-details/hc-wainwright-home-fireside-chat-w-dr-paul-peter-tak-ceo-candel-therapeutics https://ir.candeltx.com/events/event-details/hc-wainwright-home-fireside-chat-w-dr-paul-peter-tak-ceo-candel-therapeutics"  
[X Link](https://x.com/CandelTx/status/1891872863881212163)  2025-02-18T15:30Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing